COVID19 Impact - FDA and other Regulatory approvals for Indian pharma

Investec India hosted K Anand FDA and Regulatory Consultant to understand the developments on the FDA and other Regulatory approvals during the COVID19 crisis. Mr Anand explained that the Indian Pharma industry caught the attention of USA and Europe due to the proposed coronavirus medicines - HCQ and Erythromycin - requirements as these countries don’t manufacture these products. Barring coronavirus treatments, in other areas too, India has been in the spotlight of international communities. Mr Anand believes that the Indian pharma has a huge potential to rise to the occasion for supplying products to the international and domestic markets in a timely manner and win the trust of the FDA and other regulatory bodies.
Mr. Anand is the Founder and CEO of Qualiminds Corporate Services Pvt Ltd, a Mumbai based Pharma Consulting company. Before Qualimeds, Mr Anand has had a 35+ yrs. experience in quality & regulatory affairs. He has held leadership positions in various pharma giants where he was responsible for Quality, GmP compliance, regulatory affairs, technology transfer and technical operation functions.